A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction

Hyun Jun Park, Sae Woong Kim, Je-Jong Kim, Sung Won Lee, Jae Seung Paick, Tae Young Ahn, Kwangsung Park, Jong Kwan Park, Nam Cheol Park

Research output: Contribution to journalArticle

Abstract

A multi-center, randomized, double-blind, placebo-controlled study was conducted with 158 subjects who were randomized to placebo or avanafil 50, 100, and 200 mg on demand for 8 weeks to evaluate the safety, tolerability, and efficacy of avanafil in the treatment of erectile dysfunction (ED) in Korean men. The primary outcome was the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire. Secondary outcomes included changes in the scores of IIEF questions 3 and 4 (IIEF Q3, Q4) from baseline, changes in all domain scores in the IIEF from baseline, Sexual Encounter Profile questions 2-5 (SEP2-5), the Global Efficacy Assessment Question (GEAQ), and the number of subjects whose EF domain score at the 8th week visit was = 26. After 8 weeks of treatment, the dose groups except avanafil 50 mg scored significantly higher on the IIEF-EF domain from baseline than the placebo group. The changes from baseline in the avanafil group in IIEF Q3 (all doses) and Q4 (200 mg alone) were higher than the placebo group. The differences between avanafil and placebo groups were significant in SEP2 (100 and 200 mg) and SEP3-5 (200 mg). The differences in the GEAQ "Yes" response were also significant in the avanafil 100 and 200 mg groups. Regarding the ratio of normal EF at the end of the study, avanafil 200 mg differed significantly from the placebo. Most treatment-associated adverse events were mild and resolved spontaneously. This is a clinical trial study and was registered at www. ClinicalTrials.gov (Identifier: NCT02477436).

Original languageEnglish
Pages (from-to)1016-1023
Number of pages8
JournalJournal of Korean Medical Science
Volume32
Issue number6
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Erectile Dysfunction
Placebos
Safety
Therapeutics
avanafil
Clinical Trials

Keywords

  • Erectile dysfunction
  • Penile erection
  • Phosphodiesterase 5 inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction. / Park, Hyun Jun; Kim, Sae Woong; Kim, Je-Jong; Lee, Sung Won; Paick, Jae Seung; Ahn, Tae Young; Park, Kwangsung; Park, Jong Kwan; Park, Nam Cheol.

In: Journal of Korean Medical Science, Vol. 32, No. 6, 01.01.2017, p. 1016-1023.

Research output: Contribution to journalArticle

Park, Hyun Jun ; Kim, Sae Woong ; Kim, Je-Jong ; Lee, Sung Won ; Paick, Jae Seung ; Ahn, Tae Young ; Park, Kwangsung ; Park, Jong Kwan ; Park, Nam Cheol. / A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction. In: Journal of Korean Medical Science. 2017 ; Vol. 32, No. 6. pp. 1016-1023.
@article{59e63451806d4210b9fb0793b7b261d8,
title = "A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction",
abstract = "A multi-center, randomized, double-blind, placebo-controlled study was conducted with 158 subjects who were randomized to placebo or avanafil 50, 100, and 200 mg on demand for 8 weeks to evaluate the safety, tolerability, and efficacy of avanafil in the treatment of erectile dysfunction (ED) in Korean men. The primary outcome was the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire. Secondary outcomes included changes in the scores of IIEF questions 3 and 4 (IIEF Q3, Q4) from baseline, changes in all domain scores in the IIEF from baseline, Sexual Encounter Profile questions 2-5 (SEP2-5), the Global Efficacy Assessment Question (GEAQ), and the number of subjects whose EF domain score at the 8th week visit was = 26. After 8 weeks of treatment, the dose groups except avanafil 50 mg scored significantly higher on the IIEF-EF domain from baseline than the placebo group. The changes from baseline in the avanafil group in IIEF Q3 (all doses) and Q4 (200 mg alone) were higher than the placebo group. The differences between avanafil and placebo groups were significant in SEP2 (100 and 200 mg) and SEP3-5 (200 mg). The differences in the GEAQ {"}Yes{"} response were also significant in the avanafil 100 and 200 mg groups. Regarding the ratio of normal EF at the end of the study, avanafil 200 mg differed significantly from the placebo. Most treatment-associated adverse events were mild and resolved spontaneously. This is a clinical trial study and was registered at www. ClinicalTrials.gov (Identifier: NCT02477436).",
keywords = "Erectile dysfunction, Penile erection, Phosphodiesterase 5 inhibitors",
author = "Park, {Hyun Jun} and Kim, {Sae Woong} and Je-Jong Kim and Lee, {Sung Won} and Paick, {Jae Seung} and Ahn, {Tae Young} and Kwangsung Park and Park, {Jong Kwan} and Park, {Nam Cheol}",
year = "2017",
month = "1",
day = "1",
doi = "10.3346/jkms.2017.32.6.1016",
language = "English",
volume = "32",
pages = "1016--1023",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "6",

}

TY - JOUR

T1 - A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction

AU - Park, Hyun Jun

AU - Kim, Sae Woong

AU - Kim, Je-Jong

AU - Lee, Sung Won

AU - Paick, Jae Seung

AU - Ahn, Tae Young

AU - Park, Kwangsung

AU - Park, Jong Kwan

AU - Park, Nam Cheol

PY - 2017/1/1

Y1 - 2017/1/1

N2 - A multi-center, randomized, double-blind, placebo-controlled study was conducted with 158 subjects who were randomized to placebo or avanafil 50, 100, and 200 mg on demand for 8 weeks to evaluate the safety, tolerability, and efficacy of avanafil in the treatment of erectile dysfunction (ED) in Korean men. The primary outcome was the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire. Secondary outcomes included changes in the scores of IIEF questions 3 and 4 (IIEF Q3, Q4) from baseline, changes in all domain scores in the IIEF from baseline, Sexual Encounter Profile questions 2-5 (SEP2-5), the Global Efficacy Assessment Question (GEAQ), and the number of subjects whose EF domain score at the 8th week visit was = 26. After 8 weeks of treatment, the dose groups except avanafil 50 mg scored significantly higher on the IIEF-EF domain from baseline than the placebo group. The changes from baseline in the avanafil group in IIEF Q3 (all doses) and Q4 (200 mg alone) were higher than the placebo group. The differences between avanafil and placebo groups were significant in SEP2 (100 and 200 mg) and SEP3-5 (200 mg). The differences in the GEAQ "Yes" response were also significant in the avanafil 100 and 200 mg groups. Regarding the ratio of normal EF at the end of the study, avanafil 200 mg differed significantly from the placebo. Most treatment-associated adverse events were mild and resolved spontaneously. This is a clinical trial study and was registered at www. ClinicalTrials.gov (Identifier: NCT02477436).

AB - A multi-center, randomized, double-blind, placebo-controlled study was conducted with 158 subjects who were randomized to placebo or avanafil 50, 100, and 200 mg on demand for 8 weeks to evaluate the safety, tolerability, and efficacy of avanafil in the treatment of erectile dysfunction (ED) in Korean men. The primary outcome was the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire. Secondary outcomes included changes in the scores of IIEF questions 3 and 4 (IIEF Q3, Q4) from baseline, changes in all domain scores in the IIEF from baseline, Sexual Encounter Profile questions 2-5 (SEP2-5), the Global Efficacy Assessment Question (GEAQ), and the number of subjects whose EF domain score at the 8th week visit was = 26. After 8 weeks of treatment, the dose groups except avanafil 50 mg scored significantly higher on the IIEF-EF domain from baseline than the placebo group. The changes from baseline in the avanafil group in IIEF Q3 (all doses) and Q4 (200 mg alone) were higher than the placebo group. The differences between avanafil and placebo groups were significant in SEP2 (100 and 200 mg) and SEP3-5 (200 mg). The differences in the GEAQ "Yes" response were also significant in the avanafil 100 and 200 mg groups. Regarding the ratio of normal EF at the end of the study, avanafil 200 mg differed significantly from the placebo. Most treatment-associated adverse events were mild and resolved spontaneously. This is a clinical trial study and was registered at www. ClinicalTrials.gov (Identifier: NCT02477436).

KW - Erectile dysfunction

KW - Penile erection

KW - Phosphodiesterase 5 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85018439747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018439747&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.6.1016

DO - 10.3346/jkms.2017.32.6.1016

M3 - Article

VL - 32

SP - 1016

EP - 1023

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 6

ER -